Hypertension Trial, Recruiting NCT06288204 Sponsor: Universidade Federal Fluminense Condition: Hypertension
Back to Hypertension

Hypertension Trial, Recruiting

NCT06288204
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with stage 3 or stage 5 chronic kidney disease (meaning their kidneys are working at a reduced level, with a specific kidney function score between 15 and 59)
  • People who have been receiving nutrition treatment as an outpatient for at least 6 months
  • People who have been on regular kidney dialysis (hemodialysis) for at least 6 months
  • People who are taking between one and three medications to control blood pressure

Who may not be able to join:

  • People who have an autoimmune condition or an active infectious disease
  • People who have diabetes
  • People who have or have had cancer
  • People who have HIV/AIDS
  • People who are pregnant
  • People who are currently taking steroids, other medications that break down muscle or body tissue, or antibiotics
  • People who access dialysis through a catheter (a tube inserted into a vein), rather than through a surgically created access point in the arm
  • People who are currently taking antioxidant vitamin supplements, prebiotics, probiotics, or symbiotic supplements
  • People who regularly take propolis (a natural bee product) and are allergic to corn starch, or who report being allergic to bee stings
  • People who have recently had a heart attack or a stroke

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Denise Mafra, PhD, Universidade Federal Fluminense

Phone: 5521985683003

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Universidade Federal Fluminense
Registry
ClinicalTrials.gov
Start date
1 October 2024
Est. completion
31 December 2026

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

Change in factor nuclear kappaB; Change in intestinal microbiota

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov